Search Result

Results for "

BRD

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Androgen Receptor (2) Antibiotic (1) Apoptosis (38) Aurora Kinase (1) Autophagy (6) Bacterial (2) Bcl-2 Family (5) BCL6 (1) Beclin1 (1) c-Myc (4) Casein Kinase (1) Caspase (3) CDK (2) CRISPR/Cas9 (2) Dihydroorotate Dehydrogenase (2) DNA-PK (1) DNA/RNA Synthesis (5) Dopamine Receptor (1) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (8) Epigenetic Reader Domain (286) ERK (2) FKBP (2) Glutathione S-transferase (1) GSK-3 (7) HDAC (13) Hedgehog (1) Histone Acetyltransferase (11) Histone Methyltransferase (4) HIV (6) Imidazoline Receptor (1) Interleukin Related (2) Isocitrate Dehydrogenase (IDH) (1) JAK (1) Kinesin (1) LDLR (1) Ligands for E3 Ligase (2) Ligands for Target Protein for PROTAC (13) MDM-2/p53 (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Molecular Glues (6) NAMPT (1) p38 MAPK (1) Parasite (4) PARP (3) PCSK9 (1) PD-1/PD-L1 (1) Phosphodiesterase (PDE) (1) PI3K (3) Polo-like Kinase (PLK) (4) PROTAC Linkers (4) PROTAC-Linker Conjugates for PAC (5) PROTACs (85) Ribosomal S6 Kinase (RSK) (1) ROS Kinase (1) Small Interfering RNA (siRNA) (17) SNIPERs (1) Src (1) STK33 (1) Target Protein Ligand-Linker Conjugates (3)
By Research Areas:	Cancer (336) Cardiovascular Disease (6) Endocrinology (1) Infection (17) Inflammation/Immunology (39) Metabolic Disease (12) Neurological Disease (11)
Click Chemistry:	PROTAC Synthesis (2) Azide (5) Tetrazine (1) Alkynes (2)
Oligonucleotides:	Pre-designed siRNA Sets (17) siRNAs (17)

429

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-116830B

BRD5648 (R)-BRD0705	GSK-3	Cancer
BRD5648 ((R)-BRD0705) is a negative control of BRD0705. BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC₅₀ of 66 nM and a K_d of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC₅₀ of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML) .

HY-100719

BRD-6929	HDAC HIV	Infection Cardiovascular Disease
BRD-6929 is a?potent, selective brain-penetrant inhibitor of class I histone deacetylase HDAC1 and HDAC2 inhibitor with IC₅₀ of 1 nM and 8 nM, respectively. BRD-6929 shows high-affinity to HDAC1 and HDAC2 with?K_i?of 0.2 and 1.5 nM, respectively. BRD-6929 can be used for mood-related behavioral model research .

HY-141715

BRD-8000.3	Antibiotic	Infection
BRD-8000.3, as a specific EfpA inhibitor, is a narrow-spectrum, bactericidal antimycobacterial agent with good wild-type activity. BRD-8000.3 can be used for the research of tuberculosis .

HY-116455

BRD-9526	Others	Cancer
BRD-9526 is a potent and selective Sonic Hedgehog (Shh) pathway inhibitor with potential anti-cancer activity. The mechanism of BRD-9526 is similar in some ways to commonly used inhibitors such as cyclopamine, but is significantly different in other ways. The discovery of BRD-9526 may provide a useful probe for studying complex signaling pathways .

HY-162858

BRD-810	Caspase	Cancer
BRD-810 is a highly selective MCL1 inhibitor. BRD-810 can bind to the BH3 groove of MCL1 and block the sequestration of pro-apoptotic proteins, quickly inducing caspase activation in MCL1-dependent cell lines. BRD-810 shows anti-tumor activity in models of blood cancers and solid tumors .

HY-13498

BRD-8899	STK33	Cancer
BRD-8899 is a STK33 inhibitor, with an IC₅₀ of 11 nM .

HY-158141

BRD1401	Bacterial	Infection
BRD1401 is a small molecule targeting the outer membrane protein OprH. BRD1401 disrupts the interaction of OprH with LPS. BRD1401 can increase membrane fluidity .

HY-149519

BRD4 Inhibitor-28	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-28 (Compound 18) is an orally active *BRD4* Inhibitor. BRD4 Inhibitor-28 inhibits BRD40-BD1, BRD40-BD2 with IC₅₀s of 15, 55 nM. BRD4 Inhibitor-28 also inhibits BRD2-BD1, BRD3-BD1, BRDT-BD1 with IC₅₀s of 19, 25, 68 nM. BRD4 Inhibitor-28 has anti-melanoma activity .

HY-149421

BRD7-IN-3	Epigenetic Reader Domain	Cancer
BRD7-IN-3 (compound 1-78) is a dual inhibitor of bromodomain-containing proteins BRD7/BRD9 with IC₅₀s of 1.6 μM and 2.7 μM respectively .

HY-161368

BRD-SF2	PROTACs Epigenetic Reader Domain	Cancer
BRD-SF2 is a *BRD4*-targeted PROTAC degrader (DC₅₀: 17.2 μM) (Blue: VHL ligand, black: linker, pink: BRD4 ligand) .

HY-149420

BRD7-IN-2	Epigenetic Reader Domain	Others
BRD7-IN-2 (compound 2-77) is a potent inhibitor of bromodomain-containing protein 7 (BRD7), targeting to prostate cancer cells. BRD7-IN-2 is selective for BRD7 rather than BRD9, with IC50s of 5.4 μM, and >300 μM, respectively.

HY-123788

BRD5814	Dopamine Receptor	Neurological Disease
BRD5814 is a D2R antagonist. BRD5814 can be used in schizophrenia research .

HY-162734

BRD5075	Interleukin Related	Inflammation/Immunology
BRD5075 is a potent GPR65 activator. BRD5075 induces GPR65-dependent cAMP production. BRD5075 decreases the gene expression of IL-1, IL-2, TNF, and chemokine. BRD5075 has the potential for the research of multiple sclerosis and inflammatory bowel disease (IBD) .

HY-156401

BRD9 Degrader-1	Epigenetic Reader Domain	Cancer
BRD9 Degrader-1 is a *BRD9* degrader. BRD9 Degrader-1 exhibits micromolar binding affinity to BRD9 and nanomolar affinity for the ternary complex with BRD9 and VCB .

HY-162892

BRD4-IN-9	Others	Cancer
BRD4-IN-9 is an orally active *BRD4* inhibitor with an IC₅₀ value of 9.4 nM. BRD4-IN-9 can suppress tumor growth in a mouse melanoma xenograft model .

HY-160672

BRD4-IN-8	Epigenetic Reader Domain	Cancer
BRD4-IN-8 (Example 13b) is a *BRD4* inhibitor .

HY-104072

BRD4-IN-3	Epigenetic Reader Domain	Infection Inflammation/Immunology
BRD4-IN-3 (compound 141) is a potent *BRD4* inhibitor with an IC₅₀ of <0.5 µM. BRD4-IN-3 shows cytoxicity for MYC-Raji with an IC₅₀ value of >1 µM .

HY-153751

BRD4-IN-4	Epigenetic Reader Domain	Cancer
BRD4-IN-4 (Compound 1) is a *BRD4* inhibitor (IC₅₀=6.83 μM). BRD4-IN-4 selectively inhibits MV4-11 cell line proliferation and arrests cell at G1 phase. BRD4-IN-4 can be used for research of MLL leukemia .

HY-111905

BRD7-IN-1	Epigenetic Reader Domain	Cancer
BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a PROTAC VZ185 (VZ185 against BRD7/9 with DC₅₀s of 4.5 and 1.8 nM, respectively) .

HY-141843

BRD4-IN-2	Epigenetic Reader Domain	Inflammation/Immunology
BRD4-IN-2 is a bromodomain *BRD4* inhibitor with an IC₅₀ value of 9.9 nM.

HY-162735

BRD5080	Others	Inflammation/Immunology
BRD5080 is a potent GPR65 positive allosteric modulator. BRD5080 induces GPR65-dependent cAMP production. BRD5080 exhibits a robust induction of cAMP activity and recruits G protein for the WT and variant hGPR65 as well as for the mouse ortholog. BRD5080 has the potential for autoimmune and inflammatory diseases research .

HY-161938

BRD8518	PCSK9 LDLR	Metabolic Disease
BRD8518 is a PCSK9 inhibitor (EC₅₀=0.23 μM). BRD8518 lowers blood lipids by upregulating LDLR expression and stimulating LDL uptake. BRD8518 can be used in the study of cardiovascular diseases .

HY-148730

BRD7586	CRISPR/Cas9	Others
BRD7586 is a cell-permeable small-molecule inhibitor of SpCas9. BRD7586 is the smallest known anti-CRISPR .

HY-117739

BRD1652	GSK-3	Neurological Disease
BRD1652 is a highly selective GSK3 inhibitor. BRD1652 can be used in the study of emotion-related diseases .

HY-116785

BRD32048	DNA/RNA Synthesis	Cancer
BRD32048 is a direct binder of ETV1 with a K_D of 17.1 μM. BRD32048 modulates both ETV1-mediated transcriptional activity and invasion of ETV1-driven cancer cells. BRD32048 inhibits ETV1 acetylation and promotes its degradation. BRD32048 acts as a top candidate ETV1 perturbagen .

HY-160670

BRD4-IN-6	Epigenetic Reader Domain	Cancer
BRD4-IN-6 (compound 116) is a *BRD4* inhibitor (extracted from patent CN107721975A).

HY-160671

BRD4-IN-7	Epigenetic Reader Domain	Cancer
BRD4-IN-7 (compound 120) is a *BRD4* inhibitor(extracted from patent CN107721975A).

HY-155078

BRD4 Inhibitor-27	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-27 (compound 6) is a *BRD4* inhibitor with IC₅₀ of 9.6 and 11.3 μM for BRD4 BD1 and BRD4 BD2, respectively. BRD4 Inhibitor-27 has the potential to study cancer .

HY-160662

BRD4-IN-5	Epigenetic Reader Domain	Cancer
BRD4-IN-5 (example 51) is a *BRD4* inhibitor. The K_i values of the two BRD4 domains BDI_K57-E168 and BDII_E352-M457 are 9.7 nM and 16.1 nM, respectively. BRD4-IN-5 can be used in cancer research .

HY-123494

BRD0418	Others	Cardiovascular Disease Neurological Disease
BRD0418 is a diversity-oriented synthesis (DOS) molecule that regulates the expression of tribbles pseudokinase 1. BRD0418 has the effect of causing hot lipoprotein metabolism from fat production to clearance. BRD0418 can be used in the study of coronary artery disease (CAD) .

HY-163811

BRD9 Degrader-4	Epigenetic Reader Domain Molecular Glues	Cancer
BRD9 Degrader-4 (BRD9c), a bifunctional molecule, is a potent *BRD9* degrader with a DC₅₀ of ≤25 nM. BRD9 Degrader-4 has anti-cancer effects .

HY-117822

BRD0209	GSK-3	Neurological Disease
BRD0209 is a potent, selective and dual inhibitor of GSK3α/β inhibitor (GSK3α IC₅₀ = 19 nM; GSK3β IC₅₀ = 5 nM). BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics (K_i = 4.2 nM, respectively). BRD0209 is a tricyclic pyrazolotetrahydroquinolinone compound. BRD0209 has the potential for the research of mood disorder diseases .

HY-152209

BRD4 Inhibitor-26	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-26 is a bromodomain protein 4 (BRD4) inhibitor/nitric oxide-donator. BRD4 Inhibitor-26 inhibits BRD4 (BD1) and BRD4 (BD2) with IC₅₀ values of 0.82 μM and 1.94 μM, respectively. BRD4 Inhibitor-26 can be used for the research of ovarian cancer .

HY-122586

BRD6989	CDK Interleukin Related	Inflammation/Immunology
BRD6989, an analog of the natural product cortistatin A (dCA), inhibits CDK8 and upregulates IL-10. BRD6989 selectively binds a complex of CDK8 with an IC₅₀ of ~200 nM. BRD6989 inhibits the kinase activity of recombinant CDK8 or CDK19 complexes .

HY-120664

BRD50837	Hedgehog	Cancer
BRD50837 is a potent inhibitor of Sonic Hedgehog (Shh), with the EC₅₀ of 0.09 μM. BRD50837 plays an important role in cancer research .

HY-123815

BRD5459	ROS Kinase	Cancer
BRD5459 is a ROS chemical probe. BRD5459 can increase ROS, a marker of oxidative stress in cells, without causing cell death .

HY-160634

BRD4 Inhibitor-31	Epigenetic Reader Domain	Infection Inflammation/Immunology Cancer
BRD4 Inhibitor-31 (Example 136) is a *BRD4* inhibitor (K_is: 0.234 μM and 0.295 μM for BRD4 BD1 and BRD4 BD2 respectively). BRD4 Inhibitor-31 can be used for research of inflammatory diseases, cancer, and AIDS .

HY-146208

BRD4 Inhibitor-20	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-20 is a potent orally active bromodomain protein 4 (BRD4) inhibitor. BRD4 Inhibitor-20 has inhibitory activity for BRD4 (BD1) and BRD4 (BD2) with IC₅₀ values of 19 nM and 28 nM, respectively. BRD4 Inhibitor-20 also has anti-proliferation activities in cancer cell lines. BRD4 Inhibitor-20 can be used for the research of kinds of cancer, such as colon cancer .

HY-115926

BRD4 Inhibitor-16	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-16 (Compound 4) is a potent inhibitor of bromodomain 4 (BRD4). Overexpression of bromodomain 4 (BRD4) is closely correlated with a variety of human cancers by regulating the histone post-translational modifications. BRD4 Inhibitor-16 represents a useful tool for explorative studies of BRD4 inhibition, such as an improved understanding of BRD4 inhibitor release-related information .

HY-146739

BRD4 Inhibitor-19	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-19 is a BET inhibitor with an IC₅₀ of 55 nM for BRD4-BD1. BRD4 Inhibitor-19 can be used for multiple myeloma research .

HY-136857

BRD4 degrader-3	Epigenetic Reader Domain	Cancer
BRD4 degrader-3 is a potent bromodomain BRD4 degrader extracted from patent WO2020055976A1, example 1a, has IC₅₀s of 15.5 and 12.3 nM for BRD4-BD1 and BRD4-BD2, respectively . PROTAC BRD4 Degrader-7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-128597

BRD-IN-3	Epigenetic Reader Domain	Cancer
BRD-IN-3 ((R,R)-36n) is a highly potent PCAF bromodomain (BRD) inhibitor, with an IC₅₀ of 7 nM. BRD-IN-3 also exhibits activity against GCN5 and FALZ .

HY-167871

BRD4 Inhibitor-36	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-36 (Compound 185) is a *BRD4* inhibitor. BRD4 Inhibitor-36 can be used for the research of cancer .

HY-123610

BRD-7880	Aurora Kinase	Cancer
BRD-7880 is a potent and highly specific inhibitor of Aurora Kinase B (AURKB) and Aurora Kinase C (AURKC), with IC₅₀ values of 7 nM and 12 nM, respectively .

HY-145413

BRD2889	Glutathione S-transferase	Cancer
BRD2889 is an analog of the alkaloid piperlongumine. BRD2889 is a robust modulator of the GSTP1-ISCU axis in pulmonary hypertension (PH) . BRD2889 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-161515

BRD4/NAMPT-IN-1	NAMPT Epigenetic Reader Domain	Cancer
BRD4/NAMPT-IN-1 (Compound A2) shows strong inhibitory effects on NAMPT and *BRD4* (IC₅₀=35 nM (NAMPT) and 58 nM (BRD4)). BRD4/NAMPT-IN-1 inhibits the growth and migration of hepatocellular carcinoma cells and promotes apoptosis. BRD4/NAMPT-IN-1 also shows potent anticancer effects in HCCLM3 xenograft mouse model, with no obvious toxic effects .

HY-111433

BRD4 degrader AT1	PROTACs Epigenetic Reader Domain	Cancer
BRD4 degrader AT1 is a PROTAC connected by ligands for von Hippel-Lindau and *BRD4* as a highly selective *Brd4* degrader, with a K_d of 44 nM for Brd4 ^BD2 in cells.

HY-163639

BRD4 degrader-2	Molecular Glues Epigenetic Reader Domain	Cancer
BRD4 degrader-2 (Compound JP-2-197) is a covalent monovalent molecular glue *BRD4*degrader that induces a ternary complex formation between BRD4 and RNF126. BRD4 degrader-2 targets RNF126 (E3 ligase) and degrades both the long and short isoforms of BRD4 in cells .

HY-122029

BRD6897	Mitochondrial Metabolism	Metabolic Disease
BRD6897 is a mitochondrial content inducer. BRD6897 does not alter the percent of cytoplasmic area occupied by mitochondria, but instead, induces a striking increase in the electron density of existing mitochondria .

HY-147573

BRD4 Inhibitor-23	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-23 is a potent and orally active *BRD4* inhibitor with IC₅₀s of 6.21 nM and 1.44 nM for BRD4 BD-1 and BRD4 BD-2, respectively (WO2022033542A1; Example 1) .

Cat. No.	Product Name	Target	Research Area

HY-P10445

TAT-PiET	Epigenetic Reader Domain	Cancer
TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4 that disrupts the BRD4/JMJD6 interaction. BRD4/JMJD6 is a protein complex that is critical for oncogene expression and breast cancer, and TAT-PiET inhibits BRD4/JMJD6 target gene expression and breast cancer cell growth. TAT-PiET also resists endocrine resistance in ERα-positive breast cancer cells and is a potential inhibitor of breast cancer .

HY-P10446

TAT-PiET-PROTAC	Epigenetic Reader Domain	Cancer
TAT-PiET-PROTAC is a proteolysis-targeting chimera (PROTAC)-modified TAT-PiET (HY-P10445). TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of *BRD4. TAT-PiET-PROTAC can disrupt the interaction between the breast cancer oncogene BRD*4/JMJD6 and inhibit the growth of breast cancer cells. TAT-PiET-PROTAC also resists the endocrine resistance of ERα-positive breast cancer cells and is a potential inhibitor of breast cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3213

Naringenin triacetate	Structural Classification Flavonoids Classification of Application Fields Flavonones Source classification Rutaceae Plants Disease Research Fields Citrus Cancer	Epigenetic Reader Domain
Naringenin triacetate is a flavonoid isolated from plant, exhibits a good binding affinity with multiple crystal structures of first bromodomain BRD4 (BRD4 BD1) .

Species:	Virus (1) Human (4)
Tag:	His (3) GST (1) Flag (1)
Source:	E. coli (4)

Cat. No.	Compare	Product Name	Species	Source

HY-P7846

	BRD4 Protein, Human (His-Flag) 1 Publications Verification rHuBromodomain-containing protein 4/BRD4, His-Flag; HUNK1; HUNK1bromodomain-containing protein 4; HUNKI; MCAP	Human	E. coli
	The BRD4 protein is a chromatin reader that recognizes and binds acetylated histones, transmits epigenetic memory and regulates transcription during cell division. It associates with acetylated chromatin throughout the cell cycle, maintaining chromatin structure and contributing to epigenetic memory. BRD4 Protein, Human (His-Flag) is the recombinant human-derived BRD4 protein, expressed by E. coli , with N-10*His, N-Flag labeled tag.

HY-P703596

	BRD3 Protein, Human (His) KIAA0043; RING3L	Human	E. coli
	BRD3 Protein, Human (His) is the recombinant human-derived BRD3, expressed by E. coli , with His labeled tag. The total length of BRD3 Protein, Human (His) is 117 a.a.,

HY-P702877

	BRD3 Protein, Human (BD2, GST) KIAA0043; RING3L	Human	E. coli
	BRD3 Protein, Human (BD2, GST) is the recombinant human-derived BRD3, expressed by E. coli , with N-GST labeled tag. The total length of BRD3 Protein, Human (BD2, GST) is 112 a.a.,

HY-P702876

	BRD3 Protein, Human (BD2, His) KIAA0043; RING3L; Bromodomain-containing protein 3	Human	E. coli
	BRD3 Protein, Human (BD2, His) is the recombinant human-derived BRD3, expressed by E. coli , with N-6*His labeled tag. The total length of BRD3 Protein, Human (BD2, His) is 112 a.a.,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-150516S

BET-IN-12
BET-IN-12 is an orally avtive inhibitor of bromodomain and extra-terminal (BET) with an IC50 of 0.9 nM for BRD4[1].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80976

	BRD4 Antibody BRD4; CAP; HUNK1; MCAP; Bromodomain containing 4; chromosome associated protein	WB, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	BRD4 Antibody is an antibody about 152 kDa, targeting to BRD4.

HY-P80037

	BRD2 Antibody	WB, ICC/IF, IHC-P, FC	Human
	BRD2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 88 kDa, targeting to BRD2. It can be used for WB,ICC,IHC-P,FC assays with tag free, in the background of Human.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-107442

*PROTAC BRD4-binding moiety 1*		Alkynes
PROTAC BRD4-binding moiety 1 is a ligand for BRD4. PROTAC BRD4-binding moiety 1 binds to cereblon ligand via a linker to form PROTAC to degrade BRD4 (HY-133136) . PROTAC BRD4-binding moiety 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-133736

*PROTAC BRD4 Degrader-5-CO-PEG3-N3*		Azide
PROTAC BRD4 Degrader-5-CO-PEG3-N3 (Compound 2) is a PROTAC-linker Conjugate for PAC, comprises the BRD4 degrader GNE-987 and PEG-based linker . PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-101460

Tz-Thalidomide		Tetrazine
Tz-Thalidomide is a tetrazine tagged Thalidomide (HY-14658) (Ligands for E3 Ligase). Tz-Thalidomide has binding affinity for *BRD4, with IC₅₀s of 46.25 μM (BRD4-1) and 62.55 μM (BRD*4-2). Tz-Thalidomide is a click chemistry reagent, it contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups .

HY-133139

Lenalidomide-PEG1-azide		Azide
Lenalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Lenalidomide-PEG1-azide incorporates the Lenalidomide based cereblon ligand and a linker.?Lenalidomide-PEG1-azide?can be used to design a PROTAC BRD4 Degrader-2 (HY-133136) . Lenalidomide-PEG1-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-133138

Pomalidomide-PEG1-azide		Azide
Pomalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker.?Pomalidomide-PEG1-azide?can be used to design a?PROTAC BRD4 Degrader-1 (HY-133131) . Pomalidomide-PEG1-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-108369

Azido-PEG1-CH2CO2H		Azide PROTAC Synthesis
Azido-PEG1-CH2CO2H is a PROTAC linker, which refers to the alkyl/ether composition. Azido-PEG1-CH2CO2H can be used in the synthesis of PROTAC BRD4 Degrader-1 . Azido-PEG1-CH2CO2H is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-159777

CPI-203-PEG5-Alkyne		Alkynes
CPI-203-PEG5-Alkyne is a conjugate of E3 ligase and linker. CPI-203-PEG5-Alkyne can be used for synthesis of PROTAC BRD4-DCAF1 degrader-1 (HY-169151) .

HY-130984

Azido-PEG1-CH2COO-Cl		PROTAC Synthesis Azide
Azido-PEG1-CH2COO-Cl (compound 43a) is an alkyl/ether-based PROTAC linker. Azido-PEG1-CH2COO-Cl can be used in the synthesis of PROTAC BRD4 Degrader-1 (HY-133131) . Azido-PEG1-CH2COO-Cl is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BRD

Inhibitors & Agonists

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products